Dermatology biotech Dermavant Sciences postpones $100 million IPO

Shutterstock photo

Dermavant Sciences, a Phase 3 biotech developing in-licensed therapies for dermatological diseases, postponed its IPO on Thursday. It had filed to raise $100 million by offering 7.7 million shares at a price range of $12 to $14.

The Phoenix, AZ-based company was founded in 2015 and had planned to list on the Nasdaq under the symbol DRMT. Jefferies, SVB Leerink and Guggenheim Securities were set to be the joint bookrunners on the deal.

The article Dermatology biotech Dermavant Sciences postpones $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?